Recent Updates
Recently added Catalysts

Tramadol; JNS013

Phase 2

Osteoarthritis | Small molecule | Musculoskeletal |Johnson & Johnson|Last Updated: May 17, 2011

Target and mechanism

ModalitySmall molecule

Also known as Tramadol Hydrochloride; JNS013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment119

FDA Designations

No designations recorded

Clinical trial landscape

Tramadol; JNS013 · 1 trial · 2 indications

Phase 2 1
NCT00752661An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back PainOsteoarthritis
COMPLETED119 Analytics
PHASE2COMPLETED
An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain
Osteoarthritis
NCT00752661119
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change in the intensity of pain from the beginning of dose-finding period (baseline) to the final assessment point, by using VAS.

Secondary Endpoints

Percentage of patients considered analgesic effect present based on the change in VAS, VAS on each assessment day, PI (pain intensity rating), PAR (pain relief rating), PID (pain intensity difference), PRID (pain relief combined with pain intensity).
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
Tramadol Hydrochloride; JNS013DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to 74 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patients with chronic pain due to OA of the knee or LBP that persists for more than 3 months at the initiation of the observation period * Patients who received oral NSAIDs at a usual highest dose for at least 14 consecutive days during 3 months before the initiation of the ob...

Unlock Eligibility Criteria

Competitive Landscape -Osteoarthritis 114 trials

CompanyTickerTrialsLead PhaseDrugs
Eli Lilly and CompanyLLY3PHASE3Eloralintide
Pacira Biosciences, Inc.PCRX4PHASE3ZILRETTA
Novo Nordisk A/S Sponsored ADR Class BNVO1PHASE3NNC0487-0111
Bioventus, Inc. Class ABVS1PHASE2PTP-001
Enlivex Ltd.ENLV2PHASE1Allocetra
Smith & Nephew plc Sponsored ADRSNN9 - Undisclosed
Stryker CorporationSYK11N/AUndisclosed
Zimmer Biomet Holdings, Inc.ZBH57N/AUndisclosed
Merit Medical Systems, Inc.MMSI1N/ACorticosteroid
Johnson & JohnsonJNJ1N/AUndisclosed
Abbott LaboratoriesABT1N/AUndisclosed
Enovis CorporationENOV1N/AUndisclosed
Teleflex IncorporatedTFX1 - Undisclosed
Unlock Competitive Intelligence